FULC - Fulcrum Therapeutics Inc logo

FULC

Fulcrum Therapeutics Inc

Fulcrum Therapeutics develops small molecules for genetically defined disorders, focusing on treatments for sickle cell disease, beta-thalassemia, and other rare diseases. Its lead candidate, pociredir, is in clinical trials to induce fetal hemoglobin.

⚕️ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago $166today

Score Overview

1 Year
Score
Net Growth-13.51%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score3.0
Net Growth-8.51%
Net Trend40%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency
All Time
Score
Net Growth-7.44%
Net Trend43%
Net Income Consistency
Rev Growth-100.00%
Rev Trend43%
Revenue Consistency

See the full market ranking →

Fulcrum Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 8M to $ 0.00 and net income went from -$ 68M to -$ 74M. Revenue increased in 1 of those 5 years; net income in 2.

Fulcrum Therapeutics Inc currently holds a 5-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 3.72
1 Year2025-08-12
$ 6.54-43.12%
5 Years2021-08-12
$ 22.45-83.43%
All Time2019-07-18
$ 13.50-72.44%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 84M$ 318M
2025$ 0.00-$ 74M$ 352M
2024$ 80M-$ 9M$ 241M
2023$ 2M-$ 97M$ 236M
2022$ 6M-$ 109M$ 202M
2021$ 19M-$ 78M$ 218M
2020$ 8M-$ 68M$ 112M
IPO2019$ 750K-$ 79M$ 96M

Explore beyond FULC

You're looking at Fulcrum Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies